Literature DB >> 28209497

A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.

Rudy S Suidan1, Pedro T Ramirez2, Debra M Sarasohn3, Jerrold B Teitcher3, Revathy B Iyer4, Qin Zhou5, Alexia Iasonos5, John Denesopolis6, Oliver Zivanovic7, Kara C Long Roche7, Yukio Sonoda7, Robert L Coleman2, Nadeem R Abu-Rustum7, Hedvig Hricak3, Dennis S Chi8.   

Abstract

OBJECTIVE: To assess the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease (RD) at primary cytoreduction in advanced ovarian cancer.
METHODS: A prospective, non-randomized, multicenter trial of patients who underwent primary debulking for stage III-IV epithelial ovarian cancer previously identified 9 criteria associated with suboptimal (>1cm residual) cytoreduction. This is a secondary post-hoc analysis looking at the ability to predict any RD. Four clinical and 18 radiologic criteria were assessed, and a multivariate model predictive of RD was developed.
RESULTS: From 7/2001-12/2012, 350 patients met eligibility criteria. The complete gross resection rate was 33%. On multivariate analysis, 3 clinical and 8 radiologic criteria were significantly associated with the presence of any RD: age≥60years (OR=1.5); CA-125≥600U/mL (OR=1.3); ASA 3-4 (OR=1.6); lesions in the root of the superior mesenteric artery (OR=4.1), splenic hilum/ligaments (OR=1.4), lesser sac >1cm (OR=2.2), gastrohepatic ligament/porta hepatis (OR=1.4), gallbladder fossa/intersegmental fissure (OR=2); suprarenal retroperitoneal lymph nodes (OR=1.3); small bowel adhesions/thickening (OR=1.1); and moderate-severe ascites (OR=2.2). All ORs were significant with p<0.01. A 'predictive score' was assigned to each criterion based on its multivariate OR, and the rate of having any RD for patients who had a total score of 0-2, 3-5, 6-8, and ≥9 was 45%, 68%, 87%, and 96%, respectively.
CONCLUSIONS: We identified 11 criteria associated with RD, and developed a predictive model in which the rate of having any RD was directly proportional to a predictive score. This model may be helpful in treatment planning.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CA-125; CT scan; Gross residual disease; Ovarian cancer; Primary debulking

Mesh:

Substances:

Year:  2017        PMID: 28209497      PMCID: PMC5387995          DOI: 10.1016/j.ygyno.2017.02.020

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  20 in total

1.  Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.

Authors:  Suk-Joon Chang; Melissa Hodeib; Jenny Chang; Robert E Bristow
Journal:  Gynecol Oncol       Date:  2013-06-06       Impact factor: 5.482

2.  Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.

Authors:  Susan L Tucker; Kshipra Gharpure; Shelley M Herbrich; Anna K Unruh; Alpa M Nick; Erin K Crane; Robert L Coleman; Jamie Guenthoer; Heather J Dalton; Sherry Y Wu; Rajesha Rupaimoole; Gabriel Lopez-Berestein; Bulent Ozpolat; Cristina Ivan; Wei Hu; Keith A Baggerly; Anil K Sood
Journal:  Clin Cancer Res       Date:  2014-04-22       Impact factor: 12.531

3.  Multi-institutional reciprocal validation study of computed tomography predictors of suboptimal primary cytoreduction in patients with advanced ovarian cancer.

Authors:  Allison E Axtell; Margaret H Lee; Robert E Bristow; Sean C Dowdy; William A Cliby; Steven Raman; John P Weaver; Mojan Gabbay; Michael Ngo; Scott Lentz; Ilana Cass; Andrew J Li; Beth Y Karlan; Christine H Holschneider
Journal:  J Clin Oncol       Date:  2007-02-01       Impact factor: 44.544

4.  A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography.

Authors:  R E Bristow; L R Duska; N C Lambrou; E K Fishman; M J O'Neill; E L Trimble; F J Montz
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

5.  Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept.

Authors:  M Petrillo; G Vizzielli; F Fanfani; V Gallotta; F Cosentino; V Chiantera; F Legge; V Carbone; G Scambia; A Fagotti
Journal:  Gynecol Oncol       Date:  2015-07-18       Impact factor: 5.482

6.  The utility of computed tomography scans in predicting suboptimal cytoreductive surgery in women with advanced ovarian carcinoma.

Authors:  Sean C Dowdy; Sally A Mullany; Kathy R Brandt; Bonnie J Huppert; William A Cliby
Journal:  Cancer       Date:  2004-07-15       Impact factor: 6.860

7.  Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.

Authors:  Dennis S Chi; Corinna C Franklin; Douglas A Levine; Faina Akselrod; Paul Sabbatini; William R Jarnagin; Ronald DeMatteo; Elizabeth A Poynor; Nadeem R Abu-Rustum; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2004-09       Impact factor: 5.482

8.  Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  J Clin Oncol       Date:  2016-08-08       Impact factor: 44.544

9.  A multicenter prospective trial evaluating the ability of preoperative computed tomography scan and serum CA-125 to predict suboptimal cytoreduction at primary debulking surgery for advanced ovarian, fallopian tube, and peritoneal cancer.

Authors:  Rudy S Suidan; Pedro T Ramirez; Debra M Sarasohn; Jerrold B Teitcher; Svetlana Mironov; Revathy B Iyer; Qin Zhou; Alexia Iasonos; Harold Paul; Masayoshi Hosaka; Carol A Aghajanian; Mario M Leitao; Ginger J Gardner; Nadeem R Abu-Rustum; Yukio Sonoda; Douglas A Levine; Hedvig Hricak; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2014-07-11       Impact factor: 5.482

10.  Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study.

Authors:  William E Winter; G Larry Maxwell; Chunqiao Tian; Jay W Carlson; Robert F Ozols; Peter G Rose; Maurie Markman; Deborah K Armstrong; Franco Muggia; William P McGuire
Journal:  J Clin Oncol       Date:  2007-08-20       Impact factor: 44.544

View more
  32 in total

Review 1.  Cholecystectomy, porta hepatis stripping, and omental bursectomy.

Authors:  Joo-Hyuk Son; Suk-Joon Chang
Journal:  Gland Surg       Date:  2021-03

2.  Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.

Authors:  Nicole D Fleming; Alpa M Nick; Robert L Coleman; Shannon N Westin; Pedro T Ramirez; Pamela T Soliman; Bryan Fellman; Larissa A Meyer; Kathleen M Schmeler; Karen H Lu; Anil K Sood
Journal:  Obstet Gynecol       Date:  2018-09       Impact factor: 7.661

3.  Do DWI and quantitative DCE perfusion MR have a prognostic value in high-grade serous ovarian cancer?

Authors:  Francesca De Piano; Valentina Buscarino; Dulia Maresca; Patrick Maisonneuve; Giovanni Aletti; Roberta Lazzari; Andrea Vavassori; Massimo Bellomi; Stefania Rizzo
Journal:  Radiol Med       Date:  2019-08-31       Impact factor: 3.469

4.  Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.

Authors:  Diogo Torres; Chen Wang; Amanika Kumar; Jamie N Bakkum-Gamez; Amy L Weaver; Michaela E McGree; Gottfried E Konecny; Ellen L Goode; William A Cliby
Journal:  Gynecol Oncol       Date:  2018-06-18       Impact factor: 5.482

Review 5.  Prediction of optimal debulking surgery in ovarian cancer.

Authors:  Yong Jung Song
Journal:  Gland Surg       Date:  2021-03

6.  A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.

Authors:  Alli M Straubhar; Olga T Filippova; Renee A Cowan; Yulia Lakhman; Debra M Sarasohn; Ines Nikolovski; Jean M Torrisi; Weining Ma; Nadeem R Abu-Rustum; Ginger J Gardner; Yukio Sonoda; Oliver Zivanovic; Dennis S Chi; Kara Long Roche
Journal:  Gynecol Oncol       Date:  2020-06-06       Impact factor: 5.482

Review 7.  Current update on malignant epithelial ovarian tumors.

Authors:  Sherif B Elsherif; Priya R Bhosale; Chandana Lall; Christine O Menias; Malak Itani; Kristina A Butler; Dhakshinamoorthy Ganeshan
Journal:  Abdom Radiol (NY)       Date:  2021-06-05

8.  Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research.

Authors:  Shama Virani; Glauco Baiocchi; David Bowtell; Citadel J Cabasag; Kathleen R Cho; Renée T Fortner; Keiichi Fujiwara; Jae-Weon Kim; Martin Köbel; Jean-Emmanuel Kurtz; Douglas A Levine; Usha Menon; Barbara M Norquist; Paul D P Pharoah; Anil K Sood; Shelley T Tworoger; Nicolas Wentzensen; Stephen J Chanock; Paul Brennan; Britton Trabert
Journal:  Carcinogenesis       Date:  2021-06-21       Impact factor: 4.944

9.  Preoperative PET/CT score can predict complete resection in advanced epithelial ovarian cancer: a prospective study.

Authors:  Bingxin Gu; Lingfang Xia; Huijuan Ge; Shuai Liu
Journal:  Quant Imaging Med Surg       Date:  2020-03

10.  Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer.

Authors:  Nicole D Fleming; Shannon N Westin; Larissa A Meyer; Aaron Shafer; Jose Alejandro Rauh-Hain; Michaela Onstad; Lauren Cobb; Michael Bevers; Bryan M Fellman; Jennifer Burzawa; Priya Bhosale; Behrouz Zand; Amir Jazaeri; Charles Levenback; Robert L Coleman; Pamela T Soliman; Anil K Sood
Journal:  Int J Gynecol Cancer       Date:  2020-11-05       Impact factor: 3.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.